Trial · NCT05968690
Naltrexone and Propranolol Combined With Immunotherapy
NCT05968690, Phase 1, Recruiting, Sarah Weiss
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Naltrexone and Propranolol Combined With Immunotherapy. Trials, record NCT05968690. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05968690
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Naltrexone and Propranolol Combined With Immunotherapy
- NCT number
- NCT05968690
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Sarah Weiss
- Conditions
- Advanced Melanoma
- Interventions
- Propranolol, Naltrexone
- First posted
- 2023-08-01
- Last updated
- 2025-09-18
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 | initial 28 days of treatment and then for up to 2 years | |
| Primary | Dose-limiting toxicity of naltrexone in combination with propranolol and ipilimumab plus nivolumab | initial 28 days of treatment | |
| Primary | Recommended phase 2 dose of naltrexone in combination with propranolol and ipilimumab plus nivolumab | up to 2 years from start of treatment | |
| Secondary | Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 | up to 2 years from start of treatment | |
| Secondary | Progression-Free Survival (PFS) | up to 2 years from start of treatment | |
| Secondary | Overall Survival (OS) | up to 2 years from start of treatment | |
| Other | Exploratory objectives are to assess the impact of propranolol + naltrexone on the anti-tumor immune response through correlative biomarker studies performed on tumor and blood. | up to 2 years from start of treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05968690
GET https://conductscience.org/api/trials/v1/NCT05968690/registered